Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.

about

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.

Item

http://www.wikidata.org/entity/Q47101130

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Chemosensitivity to doxorubici ...... in vitro chemoresponse assay.

@en

Chemosensitivity to doxorubici ...... in vitro chemoresponse assay.

@nl

type

Item

label

Chemosensitivity to doxorubici ...... in vitro chemoresponse assay.

@en

Chemosensitivity to doxorubici ...... in vitro chemoresponse assay.

@nl

prefLabel

Chemosensitivity to doxorubici ...... in vitro chemoresponse assay.

@en

Chemosensitivity to doxorubici ...... in vitro chemoresponse assay.

@nl

P1476

Chemosensitivity to doxorubici ...... n in vitro chemoresponse assay

@en

P2093

Changik Yoon

http://www.w3.org/2001/XMLSchema#string

Hak Woo Lee

http://www.w3.org/2001/XMLSchema#string

Seung Ah Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

P304

e0187679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0187679

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29117208

http://www.w3.org/2001/XMLSchema#string

P932

5695596

http://www.w3.org/2001/XMLSchema#string